Selected publication milestones, not an exhaustive history or discovery priority claim.
1991 — Local GH can change acute forearm protein kinetics; this establishes physiology, not lasting recovery. Original PMID2003602.
1992 — GH-plus-training trial in young men adds mass and whole-body synthesis without extra muscle-strength benefit. Original PMID1550219.
1994 — Long-term GH-deficiency replacement illustrates a separate baseline-deficiency indication. Original PMID8156094.
1995 — Older-adult matched-training comparison shows additional GH mass/water change without added strength. Original PMID7864103.
1997 — Older-adult GHRH before-after findings combine selected functional changes with null metabolic and composition measures; controls remain limited. Original PMID9005976.
1998 — Ipamorelin receptor profiling and animal hormone selectivity establish a mechanistic starting point. Original PMID9849822.
1999 — Human ipamorelin pharmacodynamics show GH stimulation without physical recovery endpoints. Original PMID10496658.
1999 — Two critically ill adult trials demonstrate high-dose GH mortality harm in a distinct severe clinical context. Original PMID10477776.
2001 — Mouse secretagogue adiposity effects challenge assuming all actions are explained by GH. Original PMID11162489.
2002 — Older-adult factorial GH/sex-steroid study shows sex- and endpoint-specific findings alongside adverse effects. Original PMID12425705.
2003 — Controlled perioperative GH produces selected walking and muscle-preservation benefit with frequent dose-related side effects. Original PMID12519419.
2006 — Blinded CJC-1295 ascending-dose human trials demonstrate prolonged GH/IGF-I activity. Original PMID16352683.
2006 — CJC pulsatility measurements refine endocrine engagement without adding a clinical recovery trial. Original PMID17018654.
2008 — MK-677 increases hormones and fat-free mass while measured function remains unchanged; glycemic monitoring supplies a safety boundary. Original PMID18981485.
2009 — A CJC cohort subset adds serum-proteomic markers, not independent functional replication. Original PMID19386527.
2009 — Capromorelin shows selected older-adult functional outcomes in a different drug and predefined limitation setting. Original PMID19174493.
2010 — A blinded athlete study retains a real sprint positive, with null other performance endpoints and loss after washout. Original PMID20439575.
2013 — GH rat tendon-bone repair is null in one protocol and mechanically worse in prolonged high-dose exposure. Original PMID23636184.
2014 — Human postoperative ipamorelin does not improve its key meal-tolerance endpoint despite rodent motility support. Original PMID25331030.
2014 Jul 23-30 — Tesamorelin improves adiposity endpoints in HIV-related disease with explicit metabolic monitoring. Original PMID25038357.
2016 — Two ROMANA trials show lean-mass gains without co-primary handgrip improvement in cancer cachexia. Original PMID26906526.
2026 — A recent BPC-157/TB-500 rat component comparison finds no added combination benefit, reinforcing molecule-specific testing. Original PMID42542926.
Direct human functional outcomes for the exact combination.
Formulation equivalence between long-acting albumin-binding CJC-1295 and products sold under similar names.
Component-dismantling evidence and patient-relevant synergy rather than hormone synergy.
Adequately powered functional endpoints and distinction between contractile tissue, fluid, appetite and measured recovery.
Longer-term controlled safety and net benefit under verified product exposure.
Translation of full-length thymosinbeta4 and newer TB-500 animal mechanical results to defined human indications without treating different peptides as one class.
A preregistered blinded factorial comparison of formulation-verified CJC-1295, ipamorelin, their exact combination and placebo in a predefined adult recovery setting without diagnosed GH deficiency, with matched rehabilitation and an independently assessed functional recovery endpoint over4–24 weeks.